After years of escalating pressure and legislative debate, the Consolidated Appropriations Act of 2026 has finally landed, bringing with it a wave of reforms aimed at the powerful and often opaque world of Pharmacy Benefit Managers (PBMs). Employer groups, representing the health plans of more than
The quest for a safer method to prevent strokes has long been a paramount challenge in cardiovascular medicine, as current treatments often force a difficult trade-off between preventing blood clots and risking severe bleeding. In this high-stakes environment, a new class of anticoagulants known as
The daily reality for a post-acute care administrator often involves navigating a deluge of fragmented patient data from hospital EMRs, faxes, and referral portals, all while a ticking clock pressures them to make a high-stakes decision on admission. This single, critical choice—whether a facility c
I'm joined today by Faisal Zain, a leading expert in U.S. healthcare policy with deep insights into hospital finance and pharmaceutical pricing. We're here to unpack the recent, and for many, welcome decision by the Department of Health and Human Services to scrap its controversial 340B
A New Dawn for Discretion in Men's Health The landscape of erectile dysfunction (ED) treatment has remained relatively unchanged for decades, dominated by oral tablets that have become household names. However, the recent FDA approval of Vybrique, the first and only oral dissolving film
For decades, the intricate and often bewildering system of prescription drug pricing in the United States has been orchestrated by powerful but little-understood intermediaries whose operations remained largely shielded from public and regulatory view. These entities, known as Pharmacy Benefit
